Liminal BioSciences Inc. Common Shares
LMNL
LMNL was delisted on the 25th of September, 2023.
17 hedge funds and large institutions have $472K invested in Liminal BioSciences Inc. Common Shares in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 1 closing their positions.
122% more call options, than puts
Call options by funds: $122K | Put options by funds: $55K
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
50% less capital invested
Capital invested by funds: $934K → $472K (-$463K)
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$36.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$24.3K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$7.12K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$3.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30.8K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$28.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$16.2K |
LMNL Hedge Fund Activity: Q3 2021 in Review
17 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Liminal BioSciences Inc. Common Shares (LMNL) for Q3 2021, worth a combined $472K — down 50% from $934K a quarter earlier.
Fund positioning in LMNL was balanced in Q3 2021: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 8 trimmed.
The largest buyer was Virtu Financial, adding an estimated $36.9K. The largest seller was Susquehanna International Group, cutting an estimated $68.3K.
- 17 institutional investors held Liminal BioSciences Inc. Common Shares (LMNL) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $472K of Liminal BioSciences Inc. Common Shares stock for Q3 2021, down 50% quarter-over-quarter.
- 1 fund opened new Liminal BioSciences Inc. Common Shares positions in Q3 2021 and 1 closed out, a net change of 0 holders.
- The largest Liminal BioSciences Inc. Common Shares buyer in Q3 2021 was Virtu Financial, an estimated $36.9K added.
- The largest Liminal BioSciences Inc. Common Shares seller in Q3 2021 was Susquehanna International Group, an estimated $68.3K sold.
Based on aggregated 13F filings for Q3 2021.